BioNeutral Group Appoints Richard Hierons to Advisory Board for Euro-Asian Markets

Company Also Retains Alan Kushins as Consultant for Strategic Planning and Mergers And Acquisitions

BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, announced today the appointment of Richard Hierons to its newly established Advisory Board for Euro-Asian Markets. Hierons is based in London and has over 25 years of experience in corporate law, mergers, acquisitions and corporate finance.

Hierons will participate in all of the Advisory Board’s activities, including oversight of the legal documents associated with BioNeutral’s dealings with ANA Aquiline Ltd and Steri-7 Ltd. BioNeutral recently signed a Letter of Intent with ANA Aquiline, a European manufacturer of cleaning cloths and sponges, to integrate BioNeutral’s line of antimicrobials into its versatile toweling system and to market and sell the resulting products in both the institutional and retail sector within Germany and the United Kingdom. The Company has also signed an agreement to acquire all of the shares of Steri-7, a UK manufacturer and supplier of proprietary formulations in the disinfectant and cleaning field with sales in Europe and the Middle East. The Company has previously announced both transactions.

At the same time, BioNeutral announced that Alan Kushins has been retained by the Company as a consultant. Kushins is currently principal of ChemAssets, which specializes in the market development of undervalued chemical technologies and products. He is also managing partner at LNJ Business Development. In the past, he has served as VP of Business Development at Lonza Life Sciences Ingredients. He has also worked as a marketing manager and sales manager at Merck.

Stephen J. Browand, President and CEO of BioNeutral, stated, “We are privileged to be able to bring Richard and Alan on board the BioNeutral team. Both gentlemen have extensive hands on experience both from the legal and business development perspectives of growing a young company such as ours. We intend to harness their expertise to assist us in guiding our growth in the short and long term as we seek to expand our market presence both abroad and in the U.S.”

Additionally, BioNeutral announced that it has commenced the production of its AutoNeutral™ Odor Eliminator product, a formulation that is used in the auto industry to facilitate fast turn around of vehicles for the car rental and related automotive markets, at its long time specialty chemical contract manufacturer in New Jersey.

About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden.

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Source: Business Wire/Yahoo Finance